Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

Shin-Yeu Ong; Hong Yen Ng; Shilpa Surendran; Yeh Ching Linn; YunXin Chen; Yeow Tee Goh; Colin Diong; Sathish Kumar Gopalakrishnan

doi:10.1111/bjh.13238

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

Br J Haematol. 2015 Jun;169(5):754-6. doi: 10.1111/bjh.13238. Epub 2014 Nov 21.

Authors

Shin-Yeu Ong¹, Hong Yen Ng², Shilpa Surendran¹, Yeh Ching Linn¹, YunXin Chen¹, Yeow Tee Goh¹, Colin Diong¹, Sathish Kumar Gopalakrishnan³

Affiliations

¹ Department of Haematology, Singapore General Hospital, Singapore, Singapore.
² Department of Pharmacy, Singapore General Hospital, Singapore, Singapore.
³ Department of Haematology, Singapore General Hospital, Singapore, Singapore. [email protected].

PMID: 25413901
DOI: 10.1111/bjh.13238

No abstract available

Keywords: bortezomib; bortezomib-cyclophosphamide-dexamethasone; bortezomib-thalidomide-dexamethasone; cyclophosphamide; multiple myeloma; thalidomide.

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Multiple Myeloma / drug therapy*